AADI Bioscience AADI Bioscience AADI Bioscience
Navigation
  • The Company
  • Our Science
    • mTOR Pathway
    • nab Technology Platform
    • Publications and Abstracts
  • Our Medicine
    • Our Medicine
    • Advanced Malignant PEComa
  • Pipeline
  • Expanded Access
  • Patients
    • Overview
    • Patient Advocacy
  • Contact Us
    • General Contact
    • For Healthcare Professionals
    • Careers
Home
  • Next Post
  • Previous Post

test

September 30, 2023 / Uncategorized
1 Like

Share the Post

About the Author

Related Posts

Read More
Scott Giacobello, CPA
Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology
Read More
Dave Lennon, PhD
Improved tumor penetration, anti-tumor activity, and survival of ABI-009 (nab-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition
Mohammad Hirmand, MD
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Pacific pride: Abraxis veteran grooms dormant Celgene drug for success
ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

Comments

Comments are closed.

  • Next Post
  • Previous Post
  • Home
  • Pipeline
  • Patients
  • Contact
  • Careers
  • Terms & Conditions
  • Privacy